Bone Biologics Corporation is a developer of orthobiologic products for spine fusion markets. It is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications. It is a medical device company that is focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with demineralized bone matrix (DBM), is an osteopromotive recombinant protein that provides target specific control over bone regeneration. Its platform technology is its NELL-1, a proprietary skeletal specific growth factor which is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
Símbolo de cotizaciónBBLGW
Nombre de la empresaBone Biologics Corp
Fecha de salida a bolsaNov 27, 2015
Director ejecutivoMr. Jeffrey Frelick
Número de empleados- -
Tipo de seguridadCompany Warrant
Fin del año fiscal- -
Dirección2 Burlington Woods Dr Ste 100
CiudadBURLINGTON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal01803-4551
Teléfono17815524452
Sitio Webhttps://www.bonebiologics.com/
Símbolo de cotizaciónBBLGW
Fecha de salida a bolsaNov 27, 2015
Director ejecutivoMr. Jeffrey Frelick
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos